Flexion Therapeutics Inc (FLXN)

16.84
0.13 0.77
NASDAQ : Health Care
Prev Close 16.97
Open 17.05
Day Low/High 16.60 / 17.05
52 Wk Low/High 7.56 / 29.09
Volume 146.07K
Avg Volume 395.00K
Exchange NASDAQ
Shares Outstanding 27.52M
Market Cap 459.33M
EPS -2.10
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

Flexion (FLXN) Stock Plunged Today After Announcing Stock Offering

Flexion (FLXN) Stock Plunged Today After Announcing Stock Offering

Flexion (FLXN) stock closed sharply lower on Wednesday after announcing plans to raise $77 million from a stock offering.

Market Digging Metal and Mining Stocks

There is some good speculative trading and metals are the place to be.

Commit To Buy Flexion Therapeutics At $10, Earn 22.8% Annualized Using Options

Commit To Buy Flexion Therapeutics At $10, Earn 22.8% Annualized Using Options

Investors eyeing a purchase of Flexion Therapeutics, Inc. stock, but tentative about paying the going market price of $15.38/share, might benefit from considering selling puts among the alternative strategies at their disposal.

Flexion Therapeutics Enrolls First Patient In Phase 2 Trial Of Zilretta™ Among Type 2 Diabetes Patients With Knee Osteoarthritis

Flexion Therapeutics Enrolls First Patient In Phase 2 Trial Of Zilretta™ Among Type 2 Diabetes Patients With Knee Osteoarthritis

Study to Determine If Zilretta Can Avoid the Hyperglycemia that is Commonly Observed in Diabetic Patients Who Receive Immediate-Release Triamcinolone Acetonide (TCA) Injections for Knee Osteoarthritis

Flexion To Present Pivotal Phase 2b And Phase 3 Results For Zilretta™ At Osteoarthritis Research Society International (OARSI) 2016 World Congress

Flexion To Present Pivotal Phase 2b And Phase 3 Results For Zilretta™ At Osteoarthritis Research Society International (OARSI) 2016 World Congress

Podium presentation highlights results from pivotal clinical trials completed in patients with osteoarthritis (OA) of the knee

7 Stocks Under $10 to Trade for Breakout Gains

7 Stocks Under $10 to Trade for Breakout Gains

These stocks trading for less than $10 a share are within range of triggering big breakout trades.

Flexion Therapeutics Enters Oversold Territory (FLXN)

Flexion Therapeutics Enters Oversold Territory (FLXN)

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100.

Interesting FLXN Put And Call Options For April 15th

Interesting FLXN Put And Call Options For April 15th

Investors in Flexion Therapeutics, Inc. saw new options begin trading this week, for the April 15th expiration.

Flexion (FLXN) Stock Climbs on Phase 3 Trial Results for Osteoarthritis Treatment

Flexion (FLXN) Stock Climbs on Phase 3 Trial Results for Osteoarthritis Treatment

Flexion (FLXN) stock is advancing on heavy trading volume on Wednesday after the company said its osteoarthritis treatment met its primary endpoint during a Phase 3 clinical trial.

Flexion Therapeutics Becomes Oversold (FLXN)

Flexion Therapeutics Becomes Oversold (FLXN)

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100.

Flexion Therapeutics Enrolls First Patient In Pharmacokinetic Study Of Zilretta™ For Osteoarthritis Of The Knee

Flexion Therapeutics Enrolls First Patient In Pharmacokinetic Study Of Zilretta™ For Osteoarthritis Of The Knee

Flexion Anticipates Filing New Drug Application (NDA) With U.S. Food & Drug Administration (FDA) During Second Half of 2016 for Zilretta, its Late-Stage Lead Product Candidate